Canaccord downgraded Cara Therapeutics to Hold from Buy with a price target of $1, down from $10.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARA:
- Cara Therapeutics Halts Trials for Itch Medication Difelikefalin
- Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
- Cara Therapeutics Reports First Quarter 2024 Financial Results
- Options Volatility and Implied Earnings Moves Today, May 13, 2024
- Options Volatility and Implied Earnings Moves This Week, May 13 – May 16, 2024